IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4205
Positioning
Market Dominance
Wholesale Trade
Wholesale
$52M
Christopher T. Sharng
Natural Health Trends Corp. provides personal care, wellness, and lifestyle products under the NHT Global brand. The company sells its products directly to consumers in the United States, Canada, Mexico, Peru, Hong Kong, Taiwan, China, Singapore, Malaysia, Thailand, Vietnam, South Korea, Japan, India, Russia, Kazakhstan, and Europe.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Dates updated upon official exchange announcement.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = NHTC ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$ITRN Ituran Location & Control Ltd. | 74 | 95 | 97 | 62 | - | - | 30.4% | 17.5% | 47.8% | 21.2% | 16.8% | 5.1% | 5.1% | 0.0x | $612M | VS | |
$COR Cencora, Inc. | 70 | 84 | 77 | 70 | 21.1x | 11.8x | 123.8% | 2.2% | 3.6% | 0.8% | 0.5% | 9.3% | 0.7% | 508.0x | $60.5B | VS | |
$CENT CENTRAL GARDEN & PET CO | 70 | 84 | 95 | 48 | 5.9x | 3.5x | 10.4% | 4.6% | 31.9% | 8.0% | 5.2% | -2.2% | 0.0% | 75.0x | $2.1B | VS | |
$SNX TD SYNNEX CORP | 67 | 80 | 93 | 57 | 13.5x | 6.2x | 10.0% | 2.6% | 7.0% | 2.3% | 1.3% | 6.9% | 1.2% | 55.0x | $12.4B | VS | |
$HLF HERBALIFE LTD. | 65 | 60 | 75 | 96 | 5.0x | 1.4x | -32.4% | 6.3% | 77.7% | 9.9% | 3.4% | 2.7% | 0.0% | - | $870M | VS | |
$GIC GLOBAL INDUSTRIAL Co | 65 | 82 | 60 | 62 | 18.7x | 12.5x | 24.0% | 12.5% | 35.6% | 7.4% | 5.3% | 3.3% | 2.8% | 0.0x | $1.4B | VS | |
$JXG JX Luxventure Group Inc. | 63 | 84 | 75 | 88 | - | - | 20.4% | 11.9% | 16.8% | 7.8% | 6.2% | 56.5% | 0.0% | 22.0x | $6M | VS | |
$FERG Ferguson Enterprises Inc. /DE/ | 63 | 74 | 48 | 67 | 21.4x | 14.3x | 39.4% | 12.6% | 30.7% | 9.4% | 7.0% | 5.1% | 1.3% | 68.0x | $48.9B | VS | |
$SYY SYSCO CORP | 60 | 68 | 49 | 65 | 22.7x | 9.2x | 89.9% | 5.9% | 18.3% | 3.3% | 1.9% | 3.0% | 2.9% | 595.0x | $35.3B | VS | |
$DXPE DXP ENTERPRISES INC | 60 | 58 | 55 | 79 | 21.6x | 8.5x | 25.1% | 6.2% | 31.4% | 8.5% | 4.2% | 8.6% | 0.0% | 128.0x | $1.9B | VS | |
$NHTC NATURAL HEALTH TRENDS CORP | 34 | 43 | 16 | 17 | - | - | -1.1% | -0.7% | 73.9% | -3.6% | -0.7% | -9.5% | 17.9% | 64.0x | $52M | ||
| SECTOR BENCH | - | - | - | - | - | 19.1x | 8.2x | 8.6% | 2.7% | 22.5% | 3.3% | 1.4% | 3.3% | 0.3% | 0.5x | - | REF |
NATURAL HEALTH TRENDS CORP (NHTC) receives a "Avoid" rating with a composite score of 34.1/100. It ranks #4205 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Christopher T. Sharng
Chief Executive Officer
Labor Force
140
43
32
46
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for NHTC
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Average quality profile
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Wholesale Trade sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for NHTC.
View All RatingsMaterial decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 43 | 41 | +2NEUTRAL |
| MOMENTUM | 17 | 11 | +6ALPHA |
| VALUATION | 16 | 7 | +9ALPHA |
| INVESTMENT | 32 | 42 | -10DRAG |
| STABILITY | 46 | 42 | +4NEUTRAL |
| SHORT INT | 52 | 58 | -6DRAG |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy -1.1% (sector 8.6%)
GM 74% vs sector 22%, OM -4% vs sector 3%
Capital turnover N/A
Rev growth -10%, 10yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags NATURAL HEALTH TRENDS CORP with an Avoid rating, assigning a composite score of 34.1/100 and 1 out of 5 stars. Ranked #4205 of 7,333 stocks, NHTC falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
NHTC's quality score of 43/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -1.1% (sector avg: 8.6%), gross margins of 73.9% (sector avg: 22.5%), net margins of -0.7% (sector avg: 1.4%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
NHTC registers a value score of just 16/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 1.63x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
NATURAL HEALTH TRENDS CORP's investment score of 32/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -9.5% vs. a sector average of 3.3% and a return on assets of -0.7% (sector: 2.7%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
NATURAL HEALTH TRENDS CORP is experiencing notably weak momentum with a score of just 17/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at -9.5% year-over-year, while a beta of 0.28 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
With a stability score of 46/100, NHTC exhibits average financial resilience. Key stability metrics include a beta of 0.28 and a debt-to-equity ratio of 64.00x (sector avg: 0.5x). While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
The short interest score of 52/100 for NHTC suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include elevated leverage (D/E: 64.00x), micro-cap liquidity risk. With a $52M market cap (micro-cap), NATURAL HEALTH TRENDS CORP may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
NATURAL HEALTH TRENDS CORP offers an attractive dividend yield of 17.9%, placing it among the higher-yielding stocks in its peer group. This compares to a sector average dividend yield of 0.3%. A yield this high can provide meaningful income, but investors should verify the payout is sustainable by examining the payout ratio, free cash flow coverage, and any history of dividend cuts.
NATURAL HEALTH TRENDS CORP is a micro-cap company in the Wholesale Trade sector, ranked #0 of 50 in its sector (100th percentile) and #4205 of 7,333 overall (43rd percentile). Key comparisons include ROE of -1.1% trailing the 8.6% sector median and operating margins of -3.6% below the 3.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Wholesale Trade peers.
While NHTC currently exhibits a AVOID profile, superior opportunities exist within the WHOLESALE TRADE sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Wholesale Trade Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Value (16) would have the largest impact on the composite score.
ROE 113% BELOW SECTOR MEDIAN
Gross Margin 229% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 210% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate NATURAL HEALTH TRENDS CORP (NHTC) as Avoid with a composite score of 34.1/100 at a current price of $3.28. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in stability (46th percentile) and quality (43th percentile), which together account for the majority of the composite score. Offsetting weakness in value (16th percentile) and momentum (17th percentile) tempers our overall conviction. We assign a No Moat rating (28/100), High uncertainty, and Poor capital allocation.
Key items to watch: momentum to confirm whether the current price trend has legs; the path to profitability; valuation compression risk if growth disappoints. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
NATURAL HEALTH TRENDS CORP holds a top-quartile position (#0 of 50) within the Wholesale Trade sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 34.1/100 places it at rank #4205 in our full 7,333-stock universe. At $52M in market capitalization, NATURAL HEALTH TRENDS CORP is a small-cap player in the Wholesale Trade space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue contraction of -10% combined with momentum at the 17th percentile paints a cautious picture of the near-term business outlook. The market appears to be pricing in continued challenges, and a catalyst for reversal is not clearly visible from current data.
The margin cascade tells an important story: gross margins of 74% (+51.4pp vs sector) narrow to operating margins of -4% (-6.9pp vs sector) and net margins of -0.7%, yielding a gross-to-net conversion rate of -1%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $3.28, NATURAL HEALTH TRENDS CORP is trading at a premium to fundamental value. Our value factor score of 16/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 1.6x, P/S of 0.9x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Gross margins of 74% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
A 17.88% dividend yield provides income while you wait, and dividends historically account for a significant portion of total equity returns.
The Avoid rating (composite 34.1/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Revenue decline of -10% signals business deterioration — declining revenues make it difficult to grow into the current valuation and often precede further negative revisions.
Thin net margins of -0.7% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
We assign a High uncertainty rating to NATURAL HEALTH TRENDS CORP. Key risk factors include current negative profitability (net margin -0.7%), low beta of 0.28 — while defensive, this may indicate limited upside participation in bull markets, the combination of leverage (64% D/E) and thin margins (-0.7% net) amplifies downside risk. The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: current negative profitability (net margin -0.7%); low beta of 0.28 — while defensive, this may indicate limited upside participation in bull markets; the combination of leverage (64% D/E) and thin margins (-0.7% net) amplifies downside risk. Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 46th percentile and quality factor at the 43th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 74% provide a buffer against cost pressures; a 17.88% dividend yield anchors total return. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate NATURAL HEALTH TRENDS CORP's capital allocation as Poor. Key concerns include low returns on equity (-1.1%), negative profitability, weak asset returns (ROA -0.7%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — NATURAL HEALTH TRENDS CORP significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, NATURAL HEALTH TRENDS CORP receives a Avoid rating with a composite score of 34.1/100 (rank #4205 of 7,333). Our quantitative framework assigns a No Moat (28/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 31/100.
Our analysis does not support a constructive view on NATURAL HEALTH TRENDS CORP at this time. The combination of limited competitive advantages, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign NATURAL HEALTH TRENDS CORP a meaningful economic moat, scoring 28/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 15/20.
The strongest moat sources are margin superiority (15/20) and financial resilience (8.9/20). GM 74% vs sector 22%, OM -4% vs sector 3%. Interest coverage N/A. These pillars form the core of NATURAL HEALTH TRENDS CORP's competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (0/20) and growth durability (0.7/20). Capital turnover N/A. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect NATURAL HEALTH TRENDS CORP's moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 74% providing a solid profitability foundation, declining revenues (-10%) that pressure the earnings outlook. The margin cascade from 74% gross to -4% operating to -0.7% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality is adequate though not exceptional, with the quality factor at the 43th percentile.
The margin profile shows gross margins of 74%, operating margins of -4%, net margins of -0.7%. Return metrics include ROE of -1.1% and ROA of -0.7%. Relative to the Wholesale Trade sector, gross margins are 51.4 percentage points above the sector median of 22%, and ROE of -1.1% compares to a sector median of 8.6%.
The balance sheet reflects moderate leverage with D/E of 64%, a dividend yield of 17.88%, revenue growth of -10%. The sector median D/E is 1%, putting NATURAL HEALTH TRENDS CORP at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Weak momentum (17th percentile) suggests institutional selling pressure and unfavorable technical dynamics that may persist.
LOS ANGELES, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Natural Health Trends Corp. (NASDAQ: NHTC) (the “Company”), a leading direct-selling and e-commerce company, today announced that it has entered into an agreement to repurchase all of the shares of the Company’s common stock beneficially owned by the George K. Broady family in a negotiated transaction. The transaction was reviewed and approved by a special committee of the Company’s board of directors. Prior to the transaction, the George K. Broady
Natural Health Trends (NHTC) Q4 2025 earnings call recap: revenue uptick, restructuring nearly done, $1.5M 2026 savings, margin and cash risks.

As of Jan. 17, 2024, three stocks in the consumer staples sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro. Here’s the latest list of major overbought players in this sector. Coca-Cola Consolidated, Inc. (NASDAQ: COKE) On Nov. 1, Coca-Cola Consolidated posted an increase in quarterly sales results. The ...

Gainers Ibio Inc (NYSE: IBIO) shares rose 97% to $1.4787 after the company announced MUC16 as its latest immune-oncology target program. Universal Security Instruments, Inc. (NYSE: UUU) rose 40.6% to $3.09 after the company reported a year-over-year increase in Q3 EPS and revenues. SciSparc Ltd. (NASDAQ: SPRC) gained 25.4% to $1.1410 after the company announced its MitoCareX Bio joint venture achieved achieved its first milestone pursuant to the March 10, 2022 Founders and Investment Agreement. Cyclo Therapeutics, Inc. (NASDAQ: CYTH) surged 22.4% to $1.3952. AMC Networks Inc. (NASDAQ: AMCX) shares jumped 20.9% to $24.60 after reporting better-than-expected Q4 results. EBET, Inc. (NASDAQ: EBET) gained 18.4% to $0.6321 following strong Q4 results and guidance from DraftKings. Apexigen, Inc. (NASDAQ: APGN) jumped 15.8% to $1.10. Telephone and Data Systems, Inc. (NYSE: TDS) rose 15% to $12.80 after the company posted Q4 results and increased its common share dividend from $0.18 to $0.185. Celyad Oncology SA (NASDAQ: CYAD) jumped 14.9% to $1.31. IVERIC bio, Inc. (NASDAQ: ISEE) surged 14.9% to $22.98 after the FDA accepted the company's New Drug Application for avacincaptad pegol. Lanvin Group Holdings Limited (NYSE: LANV) gained 14.7% to $8.20. DraftKings Inc. (NASDAQ: DKNG) shares climbed 14.6% to $20.41 after the company reported better-than-expected Q4 results and raised FY23 guidance. The company reported a 31% year-over-year increase in Monthly Unique Payers. United States Cellular Corporation (NYSE: USM) gained 14.5% to $24.04 following Q4 results. Kinsale Capital Group, Inc. (NASDAQ: KNSL) jumped 13.7% to $332.00 following upbeat Q4 results. Nogin Inc (NASDAQ: NOGN) rose 13.6% to $0.7260 after the company and Seychelles Imports LLC announced an agreement under which Sychelles will utilize Nogin's Customer Data ...
NHTC posts weaker fourth-quarter 2025 results with wider losses and slimmer margins, but restructuring savings and anniversary plans hint at a potential reset.
Above 50MA
37.18%
Net New Highs
+51081